Rating Change
Goldman Sachs analysts initiated coverage on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) with a Buy rating on July 13, 2026.
Rating Change Goldman Sachs analysts initiated coverage on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) with a Buy rating on July 13, 2026. Market Context Praxis Precision…

Goldman Sachs analysts initiated coverage on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) with a Buy rating on July 13, 2026.
Praxis Precision Medicines, Inc. operates in the Healthcare sector. The stock currently trades at $313.72 with a market capitalization of $5.7B.
Analyst coverage from Goldman Sachs provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Praxis Precision Medicines, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 9 Buy, 0 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 13, 2026 | Goldman Sachs | Buy | N/A |
| Jun 29, 2026 | Needham | Buy | N/A |
| Jun 18, 2026 | RBC Capital | Outperform | N/A |
| Jun 02, 2026 | Truist Securities | Buy | N/A |
| Jun 02, 2026 | Oppenheimer | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View PRAX Stock Page
A Buy rating from Goldman Sachs reflects the analyst's outlook on Praxis Precision Medicines, Inc. (NASDAQ:PRAX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PRAX forecast page.
Current market data
NASDAQ · PRAX
$367.85
Down: -$23.10 · -6.28%
Live quote updated
Keep reading
sec_filing ·
sec_filing ·
earnings ·
analyst ·